You think of crying injection arranged in Waterbury, Vermont, USA, on Monday, April 28, 2025.
Shelby Knowles | Bloomberg | Getty images
Danish pharmaceutical giant Novo Nordisk announced plans to reduce around 9,000 roles, or approximately 11.5% of its global workforce.
“Novo Nordisk today announced a transformation throughout the company to simplify its organization, improve the speed of decision -making and reallocate resources towards the company's growth opportunities in diabetes and obesity,” said the company, which produces the damn medicine to lose weight, in a statement.
“As part of the transformation, Novo Nordisk intends to reduce global workforce by approximately 9,000 of the 78,400 positions in the company, with around 5,000 expected reductions in Denmark.”
The shares increased 4.1% at 11:45 am, London time (6:45 am et), reducing the previous losses.
The company said that the reduction of the personnel would incur a unique cost of 8 billion of zero Danish ($ 1.26 billion).
As a result of the unique costs, the company said that it now expects a growth of operational profits from the whole year from 4% to 10% to constant exchange rates, below 10% to 16% described in its results of the second quarter in August.
The review marks the first important movement of the CEO and President Maziar Mike Doustdar, who took the reins in the pharmaceutical giant last month after the surprise supervision of Lars Frúergaard Jørgensen.
Novo Nordisk, once the first engine in weight loss medications, has been struggling to maintain market share, especially in the key region of the United States, in the midst of a series of supply chain problems and a greater competition of its ELI Lilly rival and cheaper compound weight loss drugs.
Meanwhile, the firm has struggled to shake the negative feeling after a series of disappointing results of the trials for its Candidate for the next -generation obesity drug.
“Our markets are evolving, particularly in obesity, since it has become more competitive and consumer
conducted. Our company must also evolve. This means instilling a greater culture based on performance, deploying our resources more and more effectively, and prioritizing the investment where it will have the greatest impact, behind our leading therapy areas, “said Doustdar in a statement.
During a so -called Julio investor confirming his appointment, Doustdar had said that he was assuming the role with a sense of “urgency” and three key priorities. Those including defending Novo's leadership in the treatment of diabetes and obesity, promoting a high performance culture and realizing the company's cost base and impulse efficiency.
